Latest On IGM Biosciences, Inc (IGMS):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-12 18:49 EST | News | IGM Biosciences GAAP EPS of -$1.33 beats by $0.01, revenue of $0.52M misses by $0.79M | N/A |  |
| 2023-04-01 06:26 EST | News | IGM Biosciences, Inc. (IGMS) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-13 08:17 EST | News | IGM Biosciences Looks Attractive Before Phase 2 Readout | N/A | |
| 2023-01-17 16:02 EST | News | IGM Biosciences starts phase 1 trial of antibody therapy for solid tumors | N/A | |
| 2022-11-03 20:55 EST | News | IGM Biosciences GAAP EPS of -$1.32 beats by $0.13, revenue of $0.33M beats by $0.07M | N/A | |
About IGM Biosciences, Inc (IGMS):
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-1 read more...9; and strategic research collaboration and license agreement with AbCellera to discover and develop IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
General
- Name IGM Biosciences, Inc
- Symbol IGMS
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 103
- Fiscal Year EndDecember
- IPO Date2019-09-18
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://igmbio.com
Valuation
- Trailing PE 6.4
- Price/Book (Most Recent Quarter) 14.83
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.79
- Return on Assets -19%
- Return on Equity -32%
- Earnings Per Share -$71.75
- Revenue Per Share $0
- Gross Profit -22649000
- Quarterly Earnings Growth 0%
Highlights
- Market Capitalization 2.97 billion
- EBITDA -33062000
- PE Ratio -1.57
- Analyst Target Price $98.63
- Book Value Per Share $8.35
Share Statistics
- Shares Outstanding 25.49 million
- Shares Float 7.74 million
- % Held by Insiders 4334%
- % Held by Institutions 58.55%
- Shares Short 2.14 million
- Shares Short Prior Month 1.94 million
- Short Ratio 12.63
- Short % of Float 26%
- Short % of Shares Outstanding 7%
Technicals
- 52 Week High $127.11
- 52 Week Low $40.84
- 50 Day Moving Average 93.75
- 200 Day Moving Average 77.67
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
IGM Biosciences, Inc (IGMS) Dividend Calendar:
IGM Biosciences, Inc (IGMS) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
IGM Biosciences, Inc (IGMS) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
IGM Biosciences, Inc (IGMS) Chart:
IGM Biosciences, Inc (IGMS) News:
Below you will find a list of latest news for IGM Biosciences, Inc (IGMS) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
IGM Biosciences, Inc (IGMS) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest IGMS Trades:
IGM Biosciences, Inc (IGMS) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-11-05 | 8-K (Current report) | |
| 2020-11-05 | S-3 (Registration statement under Securities Act of 1933) | |
| 2020-11-05 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-11-04 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-05 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-14 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-10 | SC 13D/A (General statement of acquisition of beneficial ownership) | |
| 2020-09-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-09 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-03 | 4 (Statement of changes in beneficial ownership of securities) | |
IGM Biosciences, Inc (IGMS) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of IGM Biosciences, Inc (IGMS). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 4334%
Institutional Ownership: 5855%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-11-04 | Daniel ShinYu Chen | Chief Medical Officer | Sell | 605.00 | 50.00 | 30,250.00 | 116,473.00 | |
| 2020-11-02 | Daniel ShinYu Chen | Chief Medical Officer | Buy | 950.00 | 1.39 | 1,320.50 | 117,468.00 | |
| 2020-10-02 | Daniel ShinYu Chen | Chief Medical Officer | Sell | 1,830.00 | 73.50 | 134,505.00 | 116,518.00 | |
| 2020-10-01 | Daniel ShinYu Chen | Chief Medical Officer | Buy | 2,850.00 | 1.39 | 3,961.50 | 119,368.00 | |
| 2020-10-01 | Bruce Keyt | Chief Scientific Officer | Sell | 1,000.00 | 73.59 | 73,590.00 | 1,896.00 | |
| 2020-10-01 | BROS. ADVISORS LP BAKER | Director | Buy | 223.00 | 261,465.00 | | ||
| 2020-10-01 | BROS. ADVISORS LP BAKER | Director | Buy | 223.00 | 2,883,873.00 | | ||
| 2020-10-01 | Redmile Group, LLC | Director | Buy | 178.00 | 3,425,989.00 | | ||
| 2020-10-01 | Christina Teng Topsoe | Director | Buy | 357.00 | 35,446.00 | | ||
| 2020-10-01 | Michael Stewart Lee | Director | Buy | 178.00 | 534.00 | | ||
| 2020-10-01 | MICHAEL D LOBERG | Director | Buy | 535.00 | 535.00 | | ||
| 2020-10-01 | Jakob Haldor Topsoe | Director | Buy | 178.00 | 54,949.00 | | ||
| 2020-10-01 | M KATHLEEN BEHRENS | Director | Buy | 357.00 | 93,571.00 | | ||
| 2020-09-18 | Daniel ShinYu Chen | Chief Medical Officer | Sell | 609.00 | 77.91 | 47,447.19 | 116,518.00 | |
| 2020-09-17 | Daniel ShinYu Chen | Chief Medical Officer | Buy | 950.00 | 1.39 | 1,320.50 | 117,468.00 | |
| 2020-09-10 | Bruce Keyt | Chief Scientific Officer | Sell | 1,000.00 | 60.00 | 60,000.00 | 2,896.00 | |
| 2020-09-10 | M KATHLEEN BEHRENS | Director | Buy | 978.00 | 56.41 | 55,165.07 | 64,192.00 | |
| 2020-09-10 | M KATHLEEN BEHRENS | Director | Buy | 2,367.00 | 57.75 | 136,691.41 | 66,559.00 | |
| 2020-09-10 | M KATHLEEN BEHRENS | Director | Buy | 5,132.00 | 58.75 | 301,511.16 | 71,691.00 | |
| 2020-09-10 | M KATHLEEN BEHRENS | Director | Buy | 4,442.00 | 59.65 | 264,947.53 | 76,133.00 | |